Trimethoprim‐Sulfamethoxazole Activity and Pharmacodynamics against Glycopeptide‐Intermediate Staphylococcus aureus
dc.contributor.author | Close, Sandy J. | en_US |
dc.contributor.author | McBurney, Christopher R. | en_US |
dc.contributor.author | Garvin, Cory G. | en_US |
dc.contributor.author | Chen, David C. | en_US |
dc.contributor.author | Martin, Steven J. | en_US |
dc.date.accessioned | 2012-03-16T16:01:30Z | |
dc.date.available | 2012-03-16T16:01:30Z | |
dc.date.issued | 2002-08 | en_US |
dc.identifier.citation | Close, Sandy J.; McBurney, Christopher R.; Garvin, Cory G.; Chen, David C.; Martin, Steven J. (2002). "Trimethoprim‐Sulfamethoxazole Activity and Pharmacodynamics against Glycopeptide‐Intermediate Staphylococcus aureus ." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 22(8). <http://hdl.handle.net/2027.42/90392> | en_US |
dc.identifier.issn | 0277-0008 | en_US |
dc.identifier.issn | 1875-9114 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90392 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.title | Trimethoprim‐Sulfamethoxazole Activity and Pharmacodynamics against Glycopeptide‐Intermediate Staphylococcus aureus | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | School of Public Health, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | School of Pharmacy, University of Missouri at Kansas City, Kansas City, Missouri | en_US |
dc.contributor.affiliationother | Infectious Disease Research Laboratory, College of Pharmacy, University of Toledo, Toledo, Ohio | en_US |
dc.identifier.pmid | 12173801 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90392/1/phco.22.12.983.33599.pdf | |
dc.identifier.doi | 10.1592/phco.22.12.983.33599 | en_US |
dc.identifier.source | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | en_US |
dc.identifier.citedreference | Hershberger E., Aeschlimann J.R., Moldovan T., Rybak M.J.. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin‐sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin‐intermediate Staphylococcus aureus by time‐kill curve methods. Antimicrob Agents Chemother 1999; 13: 717 – 21. | en_US |
dc.identifier.citedreference | Kim M., Pai C.H., Woo J.H., Ryu J.S., Hiramatsu K.. Vancomycin‐intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38: 3879 – 81. | en_US |
dc.identifier.citedreference | Ellison R.T., Judson F.N., Peterson L.C., Cohn D.L., Ehret J.M.. Oral rifampin and trimethoprim‐sulfamethoxazole therapy in asymptomatic carriers of methicillin‐resistant Staphylococcus aureus infections. West J Med 1984; 140: 735 – 40. | en_US |
dc.identifier.citedreference | Tenover F.C., Lancaster M.V., Hill B.C., et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020 – 7. | en_US |
dc.identifier.citedreference | Moreira B., Boyle‐Vavra S., deJonge B.L.M., Baum R.S.. Increased production of penicillin‐binding protein 2, increased detection of other penicillin‐binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 1788 – 93. | en_US |
dc.identifier.citedreference | Cui L., Murakami H., Kuwahara‐Arai K., Hanaki H., Hiramatsu K.. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44: 2276 – 85. | en_US |
dc.identifier.citedreference | Sieradzki K., Tomasz A.. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin‐resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179: 2557 – 66. | en_US |
dc.identifier.citedreference | Boyle‐Vavra S., Berke S.K., Lee J.C., Daum R.S.. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2000; 44: 272 – 7. | en_US |
dc.identifier.citedreference | Williams D., Bergan T., Moosdeen F.. Arrival of vancomycin resistance in Staphylococcus aureus. Antibiotic Chemotherapy; Newsletter of the International Society of Chemotherapy 1997; 1 ( 2 ): 1. | en_US |
dc.identifier.citedreference | Rybak M.J., Hershberger E., Moldovan T., Grucz R.. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin‐dalfopristin against staphylococci and enterococci, including vancomycin‐intermediate and ‐resistant strains. Antimicrob Agents Chemother 2000; 44: 1062 – 6. | en_US |
dc.identifier.citedreference | Elwell L.P., Wilson H.R., Knick V.B., Keith B.R.. In vitro and in vivo efficacy of the combination trimethoprim‐sulfamethoxazole against clinical isolates of methicillin‐resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29: 1092 – 4. | en_US |
dc.identifier.citedreference | Yeldandi V., Strodtman R., Lentino J.R.. In‐vitro and in‐vivo studies of trimethoprim‐sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 22: 873 – 80. | en_US |
dc.identifier.citedreference | Tripodi M.F., Attanasio V., Adinolfi L.E., et al. Prevalence of antibiotic resistance among clinical isolates of methicillin‐resistant staphylococci. Eur J Clin Microbiol Infect Dis 1994; 13: 148 – 52. | en_US |
dc.identifier.citedreference | Scheel O., Lyon D.J., Rosdahl V.T., Adeyemi‐Doro A.B., Ling T.K., Cheng A.F.. In vitro susceptibility of isolates of methicillin‐resistant Staphylococcus aureus 1988–1993. J Antimicrob Chemother 1996; 37: 243 – 51. | en_US |
dc.identifier.citedreference | Schmitz F.J., Verhoef J., Fluit A., Heinz H.P., Jones M.E.. Stability of the MICs of various antibiotics in different clonal populations of methicillin‐resistant Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 311 – 15. | en_US |
dc.identifier.citedreference | Cohen M.A., Huband M.D.. Activity of clinafloxacin, trovafloxacin, quinupristin‐dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 1999; 33: 43 – 6. | en_US |
dc.identifier.citedreference | Markowitz N., Quinn E.L., Saravolatz L.D.. Trimethoprim‐sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390 – 8. | en_US |
dc.identifier.citedreference | Ploy M.C., Grelaud C., Martin C., de Lumley L., Denis F.. First clinical isolate of vancomycin‐intermediate Staphylococcus aureus in a French hospital [letter]. Lancet 1998; 351: 1212. | en_US |
dc.identifier.citedreference | Hess M.A., Boucher B.A., Laizure S.C., et al. Trimethoprim‐sulfamethoxazole pharmacokinetics in trauma patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1993; 13 ( 6 ): 602 – 6. | en_US |
dc.identifier.citedreference | National Committee for Clinical Laboratory Standards. Approved standard M7–A4. In: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Wayne, PA: NCCLS, 1997. | en_US |
dc.identifier.citedreference | National Committee for Clinical Laboratory Standards. Approved guidelines M26–A. In: Methods for determining bactericidal activity of antimicrobial agents. Wayne, PA: NCCLS, 1999. | en_US |
dc.identifier.citedreference | Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C.. Methicillin‐resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135 – 46. | en_US |
dc.identifier.citedreference | Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morb Mortal Wkly Rep MMWR 1997; 46: 765 – 6. | en_US |
dc.identifier.citedreference | Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morb Mortal Wkly Rep MMWR 1997; 46: 813 – 14. | en_US |
dc.identifier.citedreference | Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493 – 501. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.